This invention relates to medical devices, and in particular to such devices for use in ophthalmology.
The following documents are considered to be relevant for an understanding of the background of the invention:
Barkana, Y and Belkin M., Selective Laser Trabeculoplasty, Survey of Ophthalmology 52:634-653, 2007.
U.S. Pat. No. 6,698,886 to Pollack et al.
U.S. Pat. No. 5,479,222 to Volk.
Under normal circumstances, aqueous humor is secreted into the posterior chamber of the eye, and then circulates through the pupil into the anterior chamber where it passes through the trabecular meshwork, before being secreted from the eye. In most forms of glaucoma, the flow of the aqueous humor through the trabecular meshwork is 15 impeded, preventing adequate drainage of the aqueous humor from the eye. This leads to a rise in the intraocular pressure, a state which may cause damage to the eye and lead to progressive blindness. One method to treat or prevent this from occurring is to alter some of the trabecular meshwork in order to improve the flow of aqueous humor through the trabecular meshwork.
A common method of enhancing the flow of aqueous humor through the trabecular meshwork is laser trabeculoplasty (LTP) which consists of the application of laser energy to the trabecular meshwork. There are a several types of LTP, such as selective laser trabeculoplasty (SLT) argon laser trabeculoplasty (ALT), diode laser trabeculoplasty (DLT), micropulse laser trabeculoplasty (MLT), and titanium: sapphire laser trabeculoplasty (TLT). The various types of LTP differ in the wavelength and other characteristics of the laser beam. SLT, for example, utilizes a Q-switched 532 Nd:YAG laser which selectively targets melanin-containing cells within the trabecular meshwork. (Barkana, Y et al) While the entire mechanism of action has not been completely elucidated, it is believed that laser-stimulated melanin-containing cells release cytokines which attract other cell types to the trabecular meshwork that increase its permeability.
Unlike older versions of LTP, such as ALT, selective laser trabeculoplasty does not require precise targeting since the wavelength and energy of the light used selectively targets cells which absorb the energy of its wavelength such as the melanin-containing cells within the meshwork. The surrounding cells are not heated or destroyed. Thus, the fluid outflow is improved without damaging the trabecular meshwork. SLT has been used to treat primary open angle glaucoma, intraocular hypertension, normal tension glaucoma, aphakic (glaucoma in patients without a natural lens in their eye), pseudophakic glaucoma (glaucoma in patients without an artificial lens in their eye pigmentary, chronic angle closure glaucoma and juvenile glaucoma. SLT has also been successfully used to treat pressure increases in the eye caused by certain medications.
U.S. Pat. No. 5,479,222 to Volk discloses a gonioscopic lens system comprising at least two lenses. At least one of the lenses includes an aspheric surface of revolution. The lenses are positioned adjacent one another in a housing, such that the refractive properties of each are combined to converge light from an illumination light source to the entrance pupil of the patient's eye to illuminate the fundus. The lens system is designed for use with an associated ophthalmoscopic lens, enabling selective modification of the optical characteristics of the ophthalmoscopic lens system in a predetermined manner.
U.S. Pat. No. 6,698,886 to Pollack et al discloses an iridotomy and trabeculoplasty goniolaser lens having a contact lens element, a planar mirror offset from the optical axis of the contact lens element and first and second button lenses mounted on the anterior surface of the contact lens element. Magnification, curvature and location of the button lenses are chosen so as to provide the ability to simultaneously deliver laser energy to the iris of a patient's eye along a first optical path offset from the optical axis of the contact lens element and to view the trabecular meshwork around the region where the laser energy was applied.
Irradiating the trabecular meshwork with a laser beam directed through the cornea, as shown in
Embodiments of the present invention that are described herein provide systems and methods for treatment of the eye using laser radiation.
There is therefore provided, in accordance with an embodiment of the invention, apparatus for medical treatment, including: a laser source, which is configured to output a beam of laser radiation. An optical device is configured to direct the laser radiation to impinge on a limbal area of an eye with optical properties chosen so as to apply a desired treatment to a tissue structure associated with a cornea of the eye within the limbal area.
In a disclosed embodiment, the optical device is configured to scan the beam over at least a part of the limbal area without making any contact with the eye.
In one embodiment, the optical properties are chosen so as to irradiate a trabecular meshwork beneath the cornea with an intensity sufficient to reduce an intraocular pressure in the eye.
Additionally or alternatively, the optical properties are chosen so as to stimulate stem cells associated with the cornea, such as the stem cells associated with a stroma, an endothelium, and/or an epithelium of the cornea.
Further additionally or alternatively, the optical properties are chosen so as to irradiate an epithelium of the cornea in order to treat a condition of dry eye.
There is also provided, in accordance with an embodiment of the invention, a method for medical treatment, which includes providing a laser source, which is configured to output a beam of laser radiation. An optical device, including one or more optical elements, is applied to direct the laser radiation to impinge on a limbal area of an eye with optical properties chosen so as to apply a desired treatment to a tissue structure associated with a cornea of the eye within the limbal area.
In order to understand the invention and to see how it may be carried out in practice, embodiments will now be described, by way of non-limiting example only, with reference to the accompanying drawings, in which:
Some embodiments of the present invention provide optical devices for directing a treatment beam (or possibly multiple beams) of electromagnetic radiation to one or more regions located in the limbal area of an eye. The treatment beam typically comprises laser radiation, output by a laser source, which may be in the visible and/or the near infrared (NIR) range. The optical devices comprise beam-shaping and scanning devices that are configured and operated to direct the treatment beam to impinge on the limbal area. The beam is typically pulsed or otherwise modulated, with optical characteristics of the beam, such as the pulse power, duration and focal properties, chosen to apply a desired treatment to tissue structures associated with the cornea within the limbal area, i.e., tissues on, in and/or beneath the cornea in this area.
When the laser emits a therapeutic beam in the NIR, the device may also be configured for directing a visible aiming (guiding) beam (i.e., visible to the system or to the operator of the system), which may be continuous or modulated, towards the patient's eye. The configuration is such that the aiming beam creates an illuminated pattern on the eye defining a boundary substantially matching the limbal area, thus enabling the treatment beam(s) to be incident onto the region(s) of the limbal area. The aiming beam allows a physician to control the correct location of the illuminated pattern and accordingly to match between its boundary and the limbal area of the eye.
In some of these embodiments, the beam shaping device comprises a thin substantially circular (e.g. circular or oval-like) plate having one aperture or an array of apertures that are arranged in a spaced apart relationship along the peripheral region of the plate to overly locations around the limbal area. The apertures may have, for example, a circular cross section or an arched shape. It should be understood that apertures actually present optical windows which may be implemented as holes/perforations or regions of a desirably transmitting material. Thus apertures, having circular or arched cross-section, are transparent to electromagnetic radiation of the treatment beams of interest and allow them to pass through, while the rest of the plate is opaque to these beams. The plate with one or more apertures may be rotatable so that each aperture/transparent region can be positioned over different locations of the scleral limbus while scanning the limbal area. Alternatively, the plate may have a ring-like aperture along the periphery of the plate, in which case the treatment beam has an annular shape.
As indicated above, the plate in the regions outside the aperture(s) is opaque for the electromagnetic radiation of the treatment beam(s). As for the electromagnetic radiation of the aiming beam (i.e. visual spectrum), the configuration may be such that the plate is transparent for this radiation, thus illuminating a circular spot with its outer boundary substantially coinciding with the limbal area, i.e. being of a slightly larger diameter such that the periphery region of the plate in which the aperture(s) is/are located is aligned with the limbal area.
Alternatively, the plate in the regions outside the aperture(s) may be opaque for visual spectrum as well. In this case the aiming beam has either equal or larger diameter as compared to that of the plate and illuminates a ring-like region on the eye in the form of a circular array of small spots corresponding to the array of apertures, where the diameter of the ring-like region (or at least an inner diameter thereof) substantially coincides with the limbal area. As for the treatment radiation, it may also be in the form of a beam directed along the same optical path as the aiming beam, i.e. directed towards the illuminated pattern created by the aiming beam upon identifying that the pattern surrounds the limbal area (e.g. by manipulating the plate location and accordingly the aiming beam propagation axis).
In some embodiments, the device does not contact the eye being treated, but rather is configured to be held a predetermined distance away from the eye. The device may thus apply therapeutic radiation to the area of the limbus without bringing any part of the device or any other foreign object into contact with the eye.
In another of its aspects, the invention provides a system for treating an eye. The system of the invention includes an illumination unit including first and second sources of electromagnetic radiation producing first and second beams having first and second optical properties for respectively treating and beam aiming purposes. Also provided in the system is the above-described beam shaping device for accommodating in an optical path of the first and second beams for directing the aiming beam so as to align it with the limbus and direct the treatment beam to one or more regions along the circumference of the limbal area as “marked” by the aiming beam. The electromagnetic radiation may have a wavelength in the visible spectrum and in the near infrared spectrum between 514 and 850 nm, for example using a 532 nm Nd:YAG laser. Embodiments of the present invention advantageously provide remarkably short duration of the treatment procedure. The treatment performed by the techniques described herein can take less than a second to complete while having an immediate and long lasting effect. Alternatively, longer treatment durations can be applied, depending on therapeutic indications and system capabilities. The treatment beam may be quickly and precisely delivered to the treatment area, and this condition may be accurately maintained during the treatment, thus allowing the treatment to be quick and with the desirably high light intensity and energy as regions outside the treatment area are prevented from being reached by the treatment beam. In other embodiments, active eye tracking is used to maintain alignment of the laser with the target.
Some embodiments of the present invention may be used in the treatment of glaucoma, including both open-angle and narrow or closed-angle glaucoma. In these embodiments, as described in greater detail hereinbelow, the laser radiation penetrates through the limbal area to irradiate the trabecular meshwork of the eye with sufficient power to improve the flow of aqueous humor and thus reduce intraocular pressure.
Alternatively, however, the laser beam parameters may be chosen to treat other conditions of the corneal layers and tissue structures in the limbal area of the eye. For example, in some embodiments, the laser source and beam-shaping or scanning optics are configured for treatment of dry eye and other conditions resulting from deficiencies of the limbal epithelial cells. The treatment in such embodiments is believed to be associated with stimulation of corneal stem cells by low-level laser therapy; but the treatment is effective regardless of the actual underlying biological mechanism. Treatment of the corneal epithelium may use lower laser power levels than treatment of interior structures, such as the trabecular meshwork. Additionally or alternatively, the laser beam parameters may be chosen so as to stimulate stem cells in the corneal stroma and/or endothelium.
The following are several examples of a device of the present invention for crating structured treatment light shaped for interacting with multiple regions along a limbal area of an eye, while being guided towards the regions of the limbal area by aiming light of a different spectral range. These examples utilize masking of the light propagation path and/or optical light directing elements.
Reference is made to
The beams that interact with the sclera limbus through the apertures are treatment beams, which are of a NIR wavelength range. In order to direct the treatment beams to the regions of the sclera limbus, an aiming/guiding beam is used. This aiming beam is of a wavelength in the visual spectrum, having smaller intensity (reduced-energy) as compared to the treatment beam and serves only for properly aiming the treatment beam. The aiming beam is shaped to draw the path along the limbus. Considering the use of the opaque plate as described in the present example, the plate has a diameter corresponding to that of the eye region enclosed by the limbus, and the aiming beam has a cross-section (diameter) substantially of the diameter of the plate thus illuminating an array of small spots through the apertures in the plate 21. By appropriately manipulating the plate position, this array of spots can be aligned with the regions along the whole circumference of the limbus. When the operator sees the aiming beam positioned properly, he activates the treatment illumination. The latter may utilize a single beam which when interacting with the aperture plate becomes split into an array of narrow beams passing through the apertures to the limbus regions; or alternatively the treatment beam may be initially split into an array of beams supplied to the plate by an array of optical fibers. The desired treatment may be achieved by treating discrete regions of the limbus, or if needed the plate may be rotated thus treating the entire lumbus by scanning.
It should be noted that in any of the above-described examples, the aperture disk/plate may be made of a material transparent for visual spectrum. In this case, the aiming beam may have a diameter substantially equal to or slightly larger than that of the disk, and would illuminate a spot, the boundary of which substantially coincides with the limbus circumference.
It should be understood that, according to the invention, each one of the above-described devices 20, 24, 30 and 40 may be used to define an annulus which covers the limbal area of a patient's eye properly. The annulus is defined by usage of a shaped beam of visible light to direct the operator about where a treating beam will hit the eye, then the operator can activate the treating beam to irradiate the whole annulus or specific spots within the annulus as desired. The treatment of annular region may be achieved by using either a ring-like aperture in the plate or by using one or more apertures and rotation of the plate.
It should be noted, although not specifically shown, that in some other embodiments of the device of the invention, the structured treatment light may be created by using a beam shaping element being a refractive or diffractive optical element. The refractive or diffractive optical element may be made from glass or plastic having transmitting and refracting or diffractive optics which will create a circular beam or rapidly deliver a number of discrete beams to the limbal area. When electromagnetic radiation is incident on the refractive or diffractive optical element, the radiation exits the opposite side of the element as a beam having an annular cross section. This allows irradiation of an annulus around the limbal area by a continuous ring of light. The annulus of light may have, for example, a diameter between 9 and 13 mm, and may be from 0.5 to 2.5 mm in radial width. The lasers involved may be doubled Nd/YAG, argon or any diode emitting radiation in the visible or infrared.
In yet other embodiments of the device of the invention, an ellipsoidal or parabolic mirror can be used that when illuminated by a large spot of light scanning along a large circle will generate a small ring at its focal plane.
The optical device may be a lens through which a single point can be illuminated on the limbal area. In this case, the system may include a manipulator to allow the laser beam to be directed to a plurality of locations around the limbal area in succession to impact on a plurality of locations of the trabecular meshwork. A first point around the limbal area can be illuminated, after which, the laser beam can be directed towards a second point around the limbus, and so on. This can be done automatically and rapidly. Up to about 200 points can be illuminated simultaneously at the treatment intensity with a single laser.
Turning now to
The treatment beam 64 can have a wavelength, for example, between 514 and 850 nm. The source 62 may be a laser operative in the near infrared range, such as a 532 Nd:YAG laser.
The user input device 74 may be used to input parameters relating to the treatment. For example, a user may input the beam intensity, the number of pulses of electromagnetic radiation that is to be delivered to the eye, and the pulse rate. The user selection of the beam shaping device for use in the treatment procedure determines a number of illuminated spots around the limbus. The parameters may be stored in the memory 72. The memory may also be used to store data relating to the individual being treated, as well as any relevant observations relating to the treatment.
Each pulse duration may be between 1 and 1000 milliseconds, and the fluence of a single pulse may be 0.5 to 1 J/cm2. The total energy delivered to a single eye may be from 4 to 8 J. At this fluence, the beam 64 is not visible. (Alternatively, shorter pulses and/or higher or lower fluence may be used resulting in higher or lower delivered energy. Lower energy can be useful particularly when the system 60 is applied in treatments using low-level laser therapy, such as treating dry eye and other conditions, possibly by means of stem cell stimulation.) The second source 76 of electromagnetic radiation produces a visible light beam 78. The source 76 (or appropriate light directing element) may be temporarily positioned to direct the beam 78 towards the eye via the device 66 while manipulating the position of the device 66 until arriving to the proper position of the device 66 and thus of the illumination pattern produced by the beam 78 as described above. The device 66 is properly positioned, whether the device is in contact with the eye or not, when the beam 78 impinging on the device 66 “draws” the lumbus area contour and thus the treatment beam 64 is delivered only to the limbal area 82 of the eye 80.
In use, the device 66 is positioned at a predetermined distance from the eye, the distance ranges between less than 1 mm to 200 mm. The aiming light source 76 is activated to illuminate, with the visible beam 78, an annulus having an inner (or outer) diameter that surrounds the limbus (as described above using opaque or transparent disk for visual radiation), and while under such illumination the source 62 is activated to generate a predetermined sequence of pulses of the treatment beam 64, hitting the eye within the defined annulus.
The sources of the aiming and treatment beams, 76 and 62 respectively, are preferably activated concurrently to make sure that the treatment beam is always directed to the right region(s) in the eye. At times, a sequence is actuated that includes sequential illumination by source 76 and treatment by source 62 to different spots in the limbal area of the eye each time. At any time, the device 66 may be rotated and another sequence of one or more pulses may be generated. The process may be repeated as required in any treatment. Once the patient's eye which is to be treated is positioned properly in the optical path of the beam and the line of sight of the patient is properly directed, the whole treatment procedure using the system of the present invention lasts for only part of a second, thus enhancing the patient convenience and supplying a very effective treatment.
Although the embodiments described above refer particularly to treatment of the trabecular meshwork, the principles of the present invention may similarly be applied, mutatis mutandis, in treatment of other conditions and tissue structures associated with the cornea. For example, as noted earlier, the systems and methods described above may be adapted to treat conditions of the corneal epithelium, such as dry eye.
This application is a continuation-in-part of U.S. patent application Ser. No. 16/420,194, filed May 23, 2019, which is a continuation of U.S. patent application Ser. No. 13/669,961, filed Nov. 6, 2012 (now U.S. Pat. No. 10,363,169), which is a continuation-in-part of PCT Patent Application PCT/IL2011/000373, filed May 9, 2011, which claims the benefit of U.S. Provisional Patent Application 61/332,994, filed May 10, 2010. This application also claims the benefit of U.S. Provisional Patent Application 62/899,162, filed Sep. 12, 2019. All of these related applications are incorporated herein by reference.
Number | Name | Date | Kind |
---|---|---|---|
4587257 | DeSantis | May 1986 | A |
4848894 | Buser et al. | Jul 1989 | A |
4941093 | Marshall et al. | Jul 1990 | A |
5049147 | Danon | Sep 1991 | A |
5370641 | O'Donnell, Jr. | Dec 1994 | A |
5982789 | Marshall et al. | Nov 1999 | A |
6146375 | Juhasz | Nov 2000 | A |
6267752 | Svetliza | Jul 2001 | B1 |
6267756 | Feuerstein et al. | Jul 2001 | B1 |
6569104 | Ono et al. | May 2003 | B2 |
6676655 | McDaniel | Jan 2004 | B2 |
6899707 | Scholler et al. | May 2005 | B2 |
6942656 | Pawlowski et al. | Sep 2005 | B2 |
6948815 | Neuberger | Sep 2005 | B2 |
7027233 | Goldstein et al. | Apr 2006 | B2 |
7353829 | Wachter et al. | Apr 2008 | B1 |
7371230 | Webb et al. | May 2008 | B2 |
7693259 | Gertner | Apr 2010 | B2 |
8403921 | Palankar et al. | Mar 2013 | B2 |
8465478 | Frey et al. | Jun 2013 | B2 |
8545020 | Liesfeld et al. | Oct 2013 | B2 |
8708491 | Frey et al. | Apr 2014 | B2 |
8811657 | Teiwes et al. | Aug 2014 | B2 |
8845625 | Angeley et al. | Sep 2014 | B2 |
8903468 | Peyman | Dec 2014 | B2 |
8920407 | Raksi et al. | Dec 2014 | B2 |
8939965 | Liesfeld et al. | Jan 2015 | B2 |
8968279 | Arnoldussen | Mar 2015 | B2 |
8995618 | Gertner | Mar 2015 | B2 |
9055896 | Amthor et al. | Jun 2015 | B2 |
9192780 | McDaniel | Nov 2015 | B2 |
9351878 | Muehlhoff et al. | May 2016 | B2 |
9495743 | Angeley et al. | Nov 2016 | B2 |
9532712 | Liesfeld et al. | Jan 2017 | B2 |
9782232 | Papac | Oct 2017 | B1 |
9849032 | Schuele et al. | Dec 2017 | B2 |
9877633 | Zhao et al. | Jan 2018 | B2 |
9889043 | Frey et al. | Feb 2018 | B2 |
10022457 | Peyman | Jul 2018 | B2 |
10064757 | Berlin | Sep 2018 | B2 |
10143590 | Dick et al. | Dec 2018 | B2 |
10244991 | Shademan et al. | Apr 2019 | B2 |
10258507 | Gonzalez et al. | Apr 2019 | B2 |
10278865 | Luttrull et al. | May 2019 | B2 |
10299961 | Luttrull et al. | May 2019 | B2 |
10363169 | Belkin | Jul 2019 | B2 |
10441465 | Hart et al. | Oct 2019 | B2 |
10449091 | Angeley et al. | Oct 2019 | B2 |
10456209 | Peyman | Oct 2019 | B2 |
10478342 | Dick et al. | Nov 2019 | B2 |
10524656 | Wiltberger et al. | Jan 2020 | B2 |
10617564 | Andersen et al. | Apr 2020 | B1 |
10684449 | Curatu et al. | Jun 2020 | B2 |
10702416 | Belkin et al. | Jul 2020 | B2 |
10849789 | Dewey et al. | Dec 2020 | B2 |
10925768 | Charles | Feb 2021 | B2 |
20020013573 | Telfair et al. | Jan 2002 | A1 |
20030179344 | Van de Velde | Sep 2003 | A1 |
20030225398 | Zepkin et al. | Dec 2003 | A1 |
20040059321 | Knopp et al. | Mar 2004 | A1 |
20050185138 | Wong et al. | Aug 2005 | A1 |
20060100677 | Blumenkranz | May 2006 | A1 |
20060176913 | Souhaite et al. | Aug 2006 | A1 |
20060195076 | Blumenkranz et al. | Aug 2006 | A1 |
20060265030 | McDaniel | Nov 2006 | A1 |
20080167642 | Palanker | Jul 2008 | A1 |
20080234667 | Lang et al. | Sep 2008 | A1 |
20080255546 | Orbachevski | Oct 2008 | A1 |
20090137993 | Kurtz | May 2009 | A1 |
20090247997 | Watanabe et al. | Oct 2009 | A1 |
20100057059 | Makino | Mar 2010 | A1 |
20100076419 | Chew | Mar 2010 | A1 |
20100142767 | Fleming | Jun 2010 | A1 |
20110172649 | Schuele et al. | Jul 2011 | A1 |
20120016349 | Brownell | Jan 2012 | A1 |
20120050308 | Nakano et al. | Mar 2012 | A1 |
20130317570 | Luttrull et al. | Nov 2013 | A1 |
20140114297 | Woodley et al. | Apr 2014 | A1 |
20140128731 | Gonzalez et al. | May 2014 | A1 |
20140128851 | Wysopal | May 2014 | A1 |
20140128852 | Gooding et al. | May 2014 | A1 |
20140276681 | Schuele et al. | Sep 2014 | A1 |
20150164635 | Renke | Jun 2015 | A1 |
20150272782 | Schuele et al. | Oct 2015 | A1 |
20160067087 | Tedford | Mar 2016 | A1 |
20160089269 | Horvath et al. | Mar 2016 | A1 |
20160095752 | Srinivasan et al. | Apr 2016 | A1 |
20160354241 | Mordaunt et al. | Dec 2016 | A1 |
20160367399 | Goldshleger et al. | Dec 2016 | A1 |
20170246033 | Bor et al. | Aug 2017 | A1 |
20180085257 | Horvath et al. | Mar 2018 | A1 |
20180104477 | Kurtz et al. | Apr 2018 | A1 |
20180125708 | Bohme et al. | May 2018 | A1 |
20180207029 | Herekar et al. | Jul 2018 | A1 |
20180214305 | Schuele et al. | Aug 2018 | A1 |
20180221199 | Heacock | Aug 2018 | A1 |
20180344527 | Palanker et al. | Dec 2018 | A1 |
20190078073 | Streeter et al. | Mar 2019 | A1 |
20190105200 | Hipsley | Apr 2019 | A1 |
20190105519 | Herekar et al. | Apr 2019 | A1 |
20190142636 | Tedford et al. | May 2019 | A1 |
20190151146 | Kim | May 2019 | A1 |
20190247225 | Stobrawa et al. | Aug 2019 | A1 |
20190269554 | Goldshleger et al. | Sep 2019 | A1 |
20190358085 | Fu et al. | Nov 2019 | A1 |
20200107724 | Wiltberger et al. | Apr 2020 | A1 |
20200146887 | Horvath et al. | May 2020 | A1 |
20200306080 | Herekar et al. | Oct 2020 | A1 |
20200360187 | Schuele et al. | Nov 2020 | A1 |
20200379216 | Curatu et al. | Dec 2020 | A1 |
20230201037 | Barrett et al. | Jun 2023 | A1 |
Number | Date | Country |
---|---|---|
2015210430 | Sep 2015 | AU |
2015315113 | Mar 2016 | AU |
2017258835 | Nov 2017 | AU |
2640203 | Aug 2007 | CA |
1579351 | Feb 2005 | CN |
101411607 | Apr 2009 | CN |
102193182 | Sep 2011 | CN |
105138996 | Dec 2015 | CN |
205698218 | Nov 2016 | CN |
0689811 | Jan 1996 | EP |
1602321 | Dec 2005 | EP |
2301421 | Mar 2011 | EP |
2301424 | Mar 2011 | EP |
2301425 | Mar 2011 | EP |
1856774 | Jun 2016 | EP |
2695016 | Mar 2017 | EP |
299293 | Aug 2017 | EP |
2992931 | Aug 2017 | EP |
2391318 | Dec 2017 | EP |
2729099 | Nov 2019 | EP |
3191040 | Jul 2020 | EP |
3517081 | Nov 2020 | EP |
2854729 | Mar 2021 | EP |
2016013255 | Jan 2016 | JP |
6083823 | Feb 2017 | JP |
2018051210 | Apr 2018 | JP |
20180106113 | Oct 2018 | KR |
20190022216 | Mar 2019 | KR |
2499582 | Nov 2013 | RU |
2553507 | Jun 2015 | RU |
1993012727 | Jul 1993 | WO |
9316631 | Sep 1993 | WO |
9412092 | Jun 1994 | WO |
9416425 | Jul 1994 | WO |
9515134 | Jun 1995 | WO |
9918868 | Apr 1999 | WO |
0195842 | Dec 2001 | WO |
02064031 | Aug 2002 | WO |
02087442 | Nov 2002 | WO |
2014018104 | Jan 2004 | WO |
2004027487 | Apr 2004 | WO |
2006119584 | Nov 2006 | WO |
2006128038 | Nov 2006 | WO |
2010094353 | Aug 2010 | WO |
WO-2010094353 | Aug 2010 | WO |
2010113193 | Oct 2010 | WO |
2011017002 | Feb 2011 | WO |
2011163508 | Jun 2011 | WO |
2013035091 | Mar 2013 | WO |
2013122711 | Aug 2013 | WO |
2013165689 | Nov 2013 | WO |
2015069197 | May 2015 | WO |
2015130821 | Sep 2015 | WO |
2016018864 | Feb 2016 | WO |
2016058931 | Apr 2016 | WO |
2016156760 | Oct 2016 | WO |
2016207739 | Dec 2016 | WO |
2017031570 | Mar 2017 | WO |
2017069819 | Apr 2017 | WO |
2018005796 | Jan 2018 | WO |
2018021780 | Feb 2018 | WO |
2018152020 | Aug 2018 | WO |
2018232397 | Dec 2018 | WO |
2019109125 | Jun 2019 | WO |
2020008323 | Jan 2020 | WO |
2020012841 | Jan 2020 | WO |
2020018436 | Jan 2020 | WO |
2020050308 | Mar 2020 | WO |
202093060 | May 2020 | WO |
2020089737 | May 2020 | WO |
2020183342 | Sep 2020 | WO |
2021048723 | Mar 2021 | WO |
2021155445 | Aug 2021 | WO |
2022223690 | Oct 2022 | WO |
Entry |
---|
AU Application # 2019297135 Office Action dated Sep. 30, 2021. |
International Application # PCT/IB2021/054187 Search Report dated Jul. 30, 2021. |
Katta et al., “Optical Coherence Tomography Image-Guided Smart Laser Knife for Surgery,” Lasers in Surgery and Medicine, Wiley Online Library, pp. 1-11, Jul. 2017. |
Barnes et al., “Control of Intraocular Pressure Elevations after Argon Laser Trabeculoplasty: Comparison of Brimonidine 0.2% to Apraclonidine 1.0%,” Opthalmology, vol. 106, No. 10, pp. 2033-2037, year 1999. |
Yakopson et al., “Brimonidine 0.1% vs. Apraclonidine 0.5% for Prevention of Intraocular Pressure Elevation after Selective Laser Trabeculoplasty,” Investigative Ophthalmology & Visual Science, vol. 49, p. 1234, May 2008. |
Kim et at., “Effect of Prophylactic Topical Brimonidine (0.15%) Administration on the Development of Subconjunctival Hemorrhage after Intravitreal Injection,” Retina, The Journal for Retinal and Vitreous Diseases, vol. 31, No. 2, pp. 389-392, year 2011. |
Hong et al., “Effect of Prophylactic Brimonidine Instillation on Bleeding during Strabismus Surgery in Adults,” American Journal of Ophthalmology, vol. 144, No. 3, pp. 469-470, Sep. 2007. |
Goldsmith et al., “Anterior Chamber Width Measurement by High-Speed Optical Coherence Tomography,” Ophthalmology, vol. 112, No. 2, pp. 238-244, year 2005. |
Norden, “Effect of Prophilactic Brimonidine on Bleeding Complications and Flap Adherence After Laser in situ Keratomileusis,” Journal of Refractive Surgery, vol. 18, No. 4, pp. 468-471, Jul./Aug. 2002. |
Kohnen et al., “Internal Anterior Chamber Diameter using Optical Coherence Tomography Compared with White-To-White Distances using Automated Measurements,” Journal of Cataract & Refractive Surgery, vol. 32, pp. 1809-1813, Nov. 2006. |
Zhang et al., “Perioperative Medications for Preventing Temporarily Increased Intraocular Pressure after Laser Trabeculoplasty (Review),” Cochrane Database of Systematic Reviews 2017, issue 2, pp. 1-117, year 2017. |
Nagar et al., “A randomised, prospective study comparing selective laser trabeculoplasty with latanoprost for the control of intraocular pressure in ocular hypertension and open angle glaucoma,” British Journal of Ophthalmology, vol. 89, pp. 1413-1417, year 2005. |
Hong et al., “Repeat Selective Laser Trabeculoplasty,” Journal of Glaucoma, vol. 18, issue 3, pp. 180-183, Mar. 2009. |
Goyal et al., “Effect of primary selective laser trabeculoplasty on tonographic outflow facility—a randomised clinical trial,” British Journal of Ophthalmology, BMJ Publishing Group, vol. 94, issue 11, pp. 1-22, year 2010. |
Franco et al., “Effect of Second SLT on IOP,” Investigative Ophthalmology & Visual Science, vol. 48, pp. 1-2, May 2007. |
Chen et al., “A Comparison between 90 degrees and 180 degrees Selective Laser Trabeculoplasty,” Journal of Glaucoma, vol. 13, issue 1, p. 1, Feb. 2004. |
Mequio et al, “Efficacy of Repeat Selective Laser Trabeculoplasty,” Investigative Ophthalmology & Visual Science, vol. 48, p. 1, year 2007. |
Grulkowski et al., “Anterior segment imaging with Spectral OCT system using a high-speed CMOS camera,” Optics Express, vol. 17, No. 6, p. 4842-4858, year 2009. |
Shields et al., “Noncontact Transscleral ND:YAG Cyclophotocoagulation: A Long-Term Follow-Up of 500 Patients,” Transactions of the American Ophthalmological Society, vol. XCII, pp. 271-287, year 1994. |
Liu et al., “Real-time visual analysis of microvascular blood flow for critical care,” CVPR2015 paper as Open Access Version, provided by the Computer Vision Foundation, pp. 2217-2225, year 2015. |
Desco et al., “Effect of prophylactic brimonidine on bleeding complications after cataract surgery,” European Journal of Ophthalmology, vol. 15, pp. 228-232, year 2005. |
Pasquali et al., “Dilute brimonidine to improve patient comfort and subconjunctival hemorrhage after LASIK,” Journal of Refractive Surgery, vol. 29, pp. 469-475, year 2013. |
Sacks et al., “Non-contact direct selective laser trabeculoplasty: light propagation analysis,” Biomedical Optics Express, vol. 11, pp. 2889-2904, year 2020. |
Kasuga et al., “Trabecular Meshwork Length in Men and Women by Histological Assessment,” Current Eye Research, Early Online, pp. 1-5, Jun. 2012. |
International Application # PCT/IB2020/058300 Search Report dated Dec. 27, 2020. |
SensoMotoric Instruments GmbH (SMI), “SG 3000”, Product Flyer, pp. 1-2, year 2010. |
Ashik et al., “The precision of ophthalmic biometry using calipers,” Canadian Journal of Ophthalmology, vol. 48, Issue 6, pp. 1-13, Dec. 2013. |
Balalzsi, “Noncontact Thermal Mode Nd:YAG Laser Transscleral Cyclocoagulation in the Treatment of Glaucoma,” Ophthalmology, vol. 98, pp. 1858-1863, year 1991. |
Leung et al., “Anterior chamber angle imaging with optical coherence tomography,” Eye, vol. 25, pp. 261-267, year 2011. |
Tasman et al., “The Wills Eye Hospital Atlas of Clinical Ophthalmology,” Lippincott Williams & Wilkins, p. 158, year 2001. |
Gaasterland, “Laser Therapies: Iridotomy, Iridoplasty, and Trabeculoplasty,” as appears in “The Glaucoma Book: A Practical Evidence-Based Approach to Patient Care,” Springer, p. 722, year 2010. |
Kara, “Bleeding in Retinal Images Using Image Processing”, a Thesis submitted to the graduate school of applied sciences of Near East University, pp. 1-79, Nicosia, Larnaca, year 2019. |
Navilas Operator Manual, Document Version 2.10, 2012 OD-OS GmbH, pp. 1-94, Sep. 2012. |
Arany, “Photobiomodulation therapy: Easy to do, but difficult to get right, LaserFocusWorld, pp. 1-6, Jul. 31, 2019 downloaded from www.laserfocusworld.com/lasers-sources/article/14037967/photobiomodulation-therapyeasy-to-do-but-difficult-to-get-right pp. 22-24, year 2019”—he must have had another source****. |
Borzabadi-Farahani, “Effect of low-level laser irradiation on proliferation of human dental mesenchymal stem cells; a systemic review”, Journal of Photochemistry and Photobiology B: Biology, vol. 162, pp. 577-582, Sep. 2016. |
Ascott et al., “Trabecular Repopulation by Anterior Trabecular Meshwork Cells After Laser Trabeculoplasty”, American Journal of Ophthalmology, vol. 107, issue 1, pp. 1-6, Jan. 1989. |
International Application # PCT/IB2020/052020 Search Report dated Jun. 22, 2020. |
Cao et al., “Peripheral Iridotomy”, Medscape 25, pp. 1-12, Jun. 15, 2020 downloaded from https://emedicine.medscape.com/article/1844179-overview. |
Husain, “Laser Peripheral Iridotomy—Practical Points”, YouTube presentation, p. 1, Sep. 28, 2016 downloaded from https://www.youtube.com/watch?=Azxzsv31yls. |
Geffen et al., “Transscleral Selective Laser Trabeculoplasty Without a Gonioscopy Lens”, Glaucoma Journal, vol. 26, No. 3, pp. 201-207, Mar. 2017. |
U.S. Appl. No. 16/420,194 Office Action dated Jul. 22, 2021. |
EP Application # 20201567.3 Search Report dated Jun. 22, 2021. |
International Application # PCT/IB2021/059821 Search Report dated Apr. 7, 2022. |
U.S. Appl. No. 17/254,279 Office Action dated Dec. 20, 2021. |
AU Application # 2019297135 Office Action dated Jan. 5, 2022. |
IN Application # 202147003401 Office Action dated Jan. 13, 2022. |
CN Application #201980043641.6 Office Action dated Feb. 18, 2022. |
EP Application # 19830473.5 Search Report dated Feb. 28, 2022. |
IN Application # 201948052117 Office Action dated Feb. 16, 2022. |
SG Application # 11202010437T Office Action dated May 13, 2022. |
EP Application # 19877990.2 Search Report dated Jul. 5, 2022. |
CN Application #2019800436416 Office Action dated Aug. 17, 2022. |
U.S. Appl. No. 16/420,194 Office Action dated Aug. 5, 2022. |
CN Application # 2020800163407 Office Action dated Feb. 4, 2023. |
JP Application # 2020561860 Office Action dated Feb. 7, 2023. |
CN Application #201980070459X Office Action dated Dec. 23, 2022. |
EP Application # 20769533.9 Search Report dated Nov. 8, 2022. |
AU Application # 2020345067 Office Action dated Nov. 30, 2022. |
EP Application # 20864109.2 Search Report dated Aug. 10, 2023. |
EP Application # 20201567.3 Office Action dated Jun. 6, 2023. |
JP Application # 2020561860 Office Action dated Jun. 13, 2023. |
JP Application # 2021516473 Office Action dated Jun. 20, 2023. |
CN Application # 2020800563096 Office Action dated Jul. 1, 2023. |
Number | Date | Country | |
---|---|---|---|
20200345546 A1 | Nov 2020 | US |
Number | Date | Country | |
---|---|---|---|
61332994 | May 2010 | US | |
62899162 | Sep 2019 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 13669961 | Nov 2012 | US |
Child | 16420194 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 16420194 | May 2019 | US |
Child | 16935236 | US | |
Parent | PCT/IL2011/000373 | May 2021 | US |
Child | 13669961 | US |